Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis
Open accessAbstract
Lenalidomide, with or without prednisone, is an active therapy for patients with myelofibrosis (MF). We provide an update of a phase II study of lenalidomide plus prednisone in patients with MF, after median follow up of 9 years. Forty patients were enrolled in the study and all patients were evaluable for response. Response to the treatment was reevaluated using IWG response criteria published in 2013: quality of response improved over time and overall response rate was 35%. Response in splenomegaly was seen in 39% of patients and anemia response in 32%. The median time to treatment failure (TTF) in all patients was 8.2 months and the median duration of response was 34.6 months. Response was highly durable in some patients: six patients (15%) had TTF for more than 60 months (5 years) and three patients are still on the treatment beyond 109 months (9 years). Complete and partial responses were seen in one and five patients, respectively, but achieving deeper response was not necessary for the response to be durable. New clinical studies are needed to explore safe and well tolerated lenalidomide-based combination strategies for patients with MF.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Two other HHV8-associated neoplasms, primary effusion lymphoma and Castleman disease, have also been shown to be responsive to treatment with thalidomide analogues.
“Interestingly, two other HHV8-associated neoplasms, primary effusion lymphoma111 and Castleman disease112, have also been shown to be responsive to treatment with thalidomide analogues.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,232 · see citing works
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158 · see citing works
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933 · see citing works
WHO classification of haematolymphoid tumours
Gaillard, F., & Gerstenmaier, J. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,763 · see citing works
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103 · see citing works
Self-citationJAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825 · see citing works
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovšek, S., Kantarjian, H. M., Mesa, R. A., Pardanani, A. D., Cortes, J. E., Thomas, D. A., Estrov, Z. E., Fridman, J. S., Bradley, E. C., Erickson‐Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,165 · see citing works
Self-citationDupriez, B., Morel, P., Demory, J., Laï, J., Simon, M., Plantier, I., & Bauters, F. (1996) · Blood · doi:10.1182/blood.v88.3.1013.1013 · Cited by 523 · see citing works
Emanuel, R. M., Dueck, A. C., Geyer, H. L., Kiladjian, J., Slot, S., Zweegman, S., Boekhorst, P. A. W. T., Commandeur, S., Schouten, H. C., Sackmann, F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.3863 · Cited by 453 · see citing works
Dupriez, B., Morel, P., Demory, J., et al. (1996) · Blood · doi:10.1182/blood.v88.3.1013.bloodjournal8831013 · Cited by 407 · see citing works
Tefferi, A., Cervantes, F., Mesa, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-03-488098 · Cited by 387 · see citing works
Pathogenesis of Myelofibrosis With Myeloid Metaplasia
Tefferi, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.9316 · Cited by 290 · see citing works
Vannucchi, A. M., Kantarjian, H. M., Kiladjian, J.-J., Gotlib, J., Cervantes, F., Mesa, R. A., Sarlis, N. J., Peng, W., Sandor, V., Gopalakrishna, P., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.119545 · Cited by 260 · see citing works
Self-citationOne Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Tefferi, A., Lasho, T. L., Jimma, T., Finke, C. M., Gangat, N., Vaidya, R., Begna, K. H., Al‐Kali, A., Ketterling, R. P., Hanson, C. A., et al. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.11.001 · Cited by 260 · see citing works
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Tefferi, A., Cortes, J. E., Verstovšek, S., Mesa, R. A., Thomas, D. A., Lasho, T. L., Hogan, W. J., Litzow, M. R., Allred, J. B., Jones, D. M., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004572 · Cited by 253 · see citing works
Self-citationPomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Tefferi, A., Verstovšek, S., Barosi, G., Passamonti, F., Roboz, G. J., Gisslinger, H., PAQUETTE, R. L., Cervantes, F., Rivera, C. E., Deeg, H. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7356 · Cited by 195 · see citing works
Self-citationQuintás‐Cardama, A., Kantarjian, H. M., Manshouri, T., Thomas, D. A., Cortes, J. E., Ravandi, F., Garcia‐Manero, G., Ferrajoli, A., Bueso-Ramos, C., & Verstovšek, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6548 · Cited by 155 · see citing works
Self-citationMesa, R. A., Yao, X., Cripe, L. D., Li, C., Litzow, M. R., Paietta, E. M., Rowe, J. M., Tefferi, A., & Tallman, M. S. (2010) · Blood · doi:10.1182/blood-2010-05-287417 · Cited by 136 · see citing works
A phase-2 trial of low-dose pomalidomide in myelofibrosis
Begna, K. H., Mesa, R. A., Pardanani, A. D., Hogan, W. J., Litzow, M. R., McClure, R. F., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.254 · Cited by 110 · see citing works
Thalidomide therapy for myelofibrosis with myeloid metaplasia
Thomas, D. A., Giles, F. J., Albitar, M. X., Cortes, J. E., Verstovšek, S., Faderl, S. H., O'Brien, S. M., Garcia‐Manero, G., Keating, M. J., Pierce, S. A., et al. (2006) · Cancer · doi:10.1002/cncr.21827 · Cited by 100 · see citing works
Self-citationWHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
Bruneau, J., & Molina, T. J. (2019) · Encyclopedia of pathology · doi:10.1007/978-3-319-95309-0_3817 · Cited by 73 · see citing works
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
Daver, N. G., Cortes, J. E., Newberry, K. J., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.126821 · Cited by 63 · see citing works
Self-citationComparison of thalidomide and lenalidomide as therapy for myelofibrosis
Jabbour, E. J., Thomas, D. A., Kantarjian, H. M., Zhou, L., Pierce, S. A., Cortes, J. E., & Verstovšek, S. (2011) · Blood · doi:10.1182/blood-2010-12-325589 · Cited by 56 · see citing works
Self-citationTefferi, A., Passamonti, F., Barbui, T., et al. (2013) · Blood · doi:10.1182/blood.v122.21.394.394 · Cited by 27 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works
- Authors
- Chihara, D., Masarova, L., Newberry, K. J., Maeng, H., Ravandi, F., Garcia-Manero, G., Ferrajoli, A., Cortes, J., Kantarjian, H., & Verstovsek, S.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- Leukemia Research
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 48
- Pages
- 1-5
- ISSN
- 0145-2126 (ISSN-L)
- PMC
- PMC5407688
- OpenAlex
- W2474859359
- Cited by
- 21
- References
- 24
- Citations by year
- 2026: 1 · 2024: 2 · 2022: 2 · 2021: 5 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 3 · 2016: 3
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Leukemia Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (P30CA016672)
- Topics
- Health Sciences › Medicine › Genetics › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- lenalidomide, prednisone, myelofibrosis, long-term treatment outcomes, splenomegaly, anemia, treatment durability, time to treatment failure, combination therapy
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prednisone, Remission Induction, Thalidomide, Treatment Outcome, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
